Paying user area
Try for free
Eli Lilly & Co. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Profitability Ratios
- Analysis of Solvency Ratios
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Eli Lilly & Co. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Total Eli Lilly and Company shareholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 23, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 29, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Eli Lilly & Co. Annual Report.
The price-to-book value (P/BV) ratio for the period examined exhibits considerable fluctuation. Initially, the ratio demonstrates a decreasing trend from 2006 to 2008, followed by a period of volatility before increasing significantly in later years. A detailed examination reveals distinct phases in the ratio’s behavior.
- Early Period (2006-2008)
- From 2006 to 2008, the P/BV ratio declined from 5.85 to 4.16. This decrease suggests a relative weakening of investor confidence in the company’s ability to generate value from its net assets, or potentially a decrease in market valuation relative to book value. The decline occurred alongside a rise in book value per share, indicating the share price decreased at a faster rate than the underlying asset value.
- Volatility and Recovery (2009-2012)
- The period between 2009 and 2012 shows considerable volatility. The ratio increased from 5.01 in 2009 to 3.35 in 2012, with fluctuations in both share price and book value per share contributing to this pattern. The financial crisis of 2008-2009 likely influenced this volatility, impacting both market valuations and the company’s reported book value. The ratio remained relatively contained within a narrow range during this period.
- Moderate Growth (2013-2017)
- From 2013 to 2017, the P/BV ratio generally increased, moving from 3.69 to 6.33. This upward trend suggests improving investor sentiment and a strengthening relationship between market valuation and book value. Both share price and book value per share increased during this period, but the share price experienced a more substantial rate of growth.
- Significant Expansion (2018-2023)
- The most dramatic changes are observed between 2018 and 2023. The P/BV ratio experienced a substantial surge, peaking at 65.80 in 2023. This increase was driven by a significant increase in share price, particularly in the later years, coupled with fluctuations in book value per share. The ratio increased from 7.33 in 2018 to 12.87 in 2019, then experienced an extraordinary jump to 51.67 in 2020, followed by 35.07 in 2021, 25.28 in 2022, and finally 29.36 in 2023. This suggests a substantial re-evaluation of the company by the market, potentially driven by positive developments in its business or industry outlook.
- Recent Moderation (2024-2026)
- The most recent years, 2024 through the projected 2026, show a moderation of the P/BV ratio. The ratio decreased from 65.80 in 2023 to 57.93 in 2024, and is projected to further decrease to 36.91 in 2026. This suggests a potential correction in market valuation, or a more balanced assessment of the company’s future prospects. Book value per share increased significantly during this period, partially offsetting the decline in the ratio.
Overall, the P/BV ratio demonstrates a complex pattern of change over the examined period. The initial decline, followed by volatility, moderate growth, and a period of substantial expansion, culminating in recent moderation, indicates a dynamic interplay between market sentiment, company performance, and broader economic conditions.
Comparison to Competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | ||||||||||||
| Feb 19, 2025 | ||||||||||||
| Feb 21, 2024 | ||||||||||||
| Feb 22, 2023 | ||||||||||||
| Feb 23, 2022 | ||||||||||||
| Feb 17, 2021 | ||||||||||||
| Feb 19, 2020 | ||||||||||||
| Feb 19, 2019 | ||||||||||||
| Feb 20, 2018 | ||||||||||||
| Feb 21, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 19, 2015 | ||||||||||||
| Feb 19, 2014 | ||||||||||||
| Feb 21, 2013 | ||||||||||||
| Feb 24, 2012 | ||||||||||||
| Feb 22, 2011 | ||||||||||||
| Feb 22, 2010 | ||||||||||||
| Feb 27, 2009 | ||||||||||||
| Feb 29, 2008 | ||||||||||||
| Feb 28, 2007 | ||||||||||||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 12, 2026 | ||
| Feb 19, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 17, 2021 | ||
| Feb 19, 2020 | ||
| Feb 19, 2019 | ||
| Feb 20, 2018 | ||
| Feb 21, 2017 | ||
| Feb 19, 2016 | ||
| Feb 19, 2015 | ||
| Feb 19, 2014 | ||
| Feb 21, 2013 | ||
| Feb 24, 2012 | ||
| Feb 22, 2011 | ||
| Feb 22, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Feb 28, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Feb 12, 2026 | ||
| Feb 19, 2025 | ||
| Feb 21, 2024 | ||
| Feb 22, 2023 | ||
| Feb 23, 2022 | ||
| Feb 17, 2021 | ||
| Feb 19, 2020 | ||
| Feb 19, 2019 | ||
| Feb 20, 2018 | ||
| Feb 21, 2017 | ||
| Feb 19, 2016 | ||
| Feb 19, 2015 | ||
| Feb 19, 2014 | ||
| Feb 21, 2013 | ||
| Feb 24, 2012 | ||
| Feb 22, 2011 | ||
| Feb 22, 2010 | ||
| Feb 27, 2009 | ||
| Feb 29, 2008 | ||
| Feb 28, 2007 | ||
| Mar 1, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).